Perioperative Eltrombopag in Patients With Inherited Thrombocytopenia

PHASE2CompletedINTERVENTIONAL
Enrollment

13

Participants

Timeline

Start Date

August 2, 2019

Primary Completion Date

June 27, 2023

Study Completion Date

June 27, 2023

Conditions
Thrombocytopenia
Interventions
DRUG

Eltrombopag

"Eltrombopag will be prescribed at doses recommended in primary immune thrombocytopenia (50, 25 or 75 mg), starting 4 weeks before the procedure and stopped 2 days before. PC will be administrated prophylactically if the platelet count is \< 80 G/L or per/post-operatively in case of bleeding of undetermined cause.~Antifibrinolytics will be authorized and low molecular weight heparin prescribed if indicated for the prophylaxis of postoperative venous thrombosis according to the standard dose and duration, , irrespective of the platelet count"

Trial Locations (25)

Unknown

Angers Hospital, Angers

Bensancon Hospital, Besançon

Bordeaux Hospital, Bordeaux

Caen Hospital, Caen

Clermont-Ferrand Hospital, Clermont-Ferrand

Dijon Hospital, Dijon

Lille Hospital, Lille

Hospices Civils Lyon, Lyon

Marseille Hospital, Marseille

Montpellier Hospital, Montpellier

Nancy Hospital, Nancy

Nantes Hospital, Nantes

Cochin Hospital, Paris

Hopital Europeen G Pompidou, Paris

Kremlin Bicetre Hospital, Paris

Necker Hospital, Paris

Robert Debré Hospital, Paris

Trousseau Hospital, Paris

Poitiers Hospital, Poitiers

Reims Hospital, Reims

Rennes Hospital, Rennes

Rouen Hospital, Rouen

Strasbourg Hospital, Strasbourg

university hospital Toulouse, Toulouse

Tours Hospital, Tours

All Listed Sponsors
collaborator

French network for inherited hemorragic diseases

UNKNOWN

collaborator

National Reference Centre for Platelet Pathologies

UNKNOWN

lead

University Hospital, Toulouse

OTHER

NCT03638817 - Perioperative Eltrombopag in Patients With Inherited Thrombocytopenia | Biotech Hunter | Biotech Hunter